Voyager Therapeutics Stock News

Novartis is paying Voyager Therapeutics $53 million up front to begin a partnership focused on the discovery of capsids for central nervous system disorder gene therapies. Depending on the progress of the research, Voyager could earn up to $1.5 billion in milestone payments.

Gainers: Hycroft Mining Holding (HYMC) +111%.Enservco ENSV +92%.Westport Fuel Systems (WPRT) +54%.Nine Energy Service NINE +38%.Voyager Therapeutics VYGR +32%.PolyMet Mining…

Gainers Enservco Corporation (NYSE: ENSV ) surged 228% to $8.20 after jumping around 85% on Monday. Hycroft Mining Holding Corporation (NASDAQ: HYMC ) rose 168% to $0.8850. Hycroft recently reported preliminary FY21 operating results. Nine Energy Service, Inc. (NYSE: NINE ) jumped 105.9% to $7.39 after the company reported upbeat Q4 results. The company’s stock jumped over 99% on Monday. U.S. Energy Corp. (NASDAQ: USEG ) gained 77.4% to $11.21. TMC the metals company Inc. (NASDAQ: TMC ) rose 57% to $2.5912 after climbing 18% on Monday. Marine Petroleum Trust (NASDAQ: MARPS ) rose 56.8% to $18.98 after jumping around 70% on Monday. Polar Power, Inc. (NASDAQ: POLA ) gained 52% to $6.24 on continued momentum as a surge in oil prices lifts alternative energy names. Sunworks, Inc. (NYSE: SUNW ) surged 48% to $4.65. amid continued market volatility stemming from the Russia-Ukraine war. US President Biden confirmed a ban on Russian oil imports. Independence Contract Drilling, Inc. (NYSE: ICD ) gained 44% to $7.25.

Gainers: Voyager Therapeutics VYGR +22%. 908 Devices (MASS) +16%. Viemed Healthcare VMD +10%

NEW YORK , March 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VYGR, IO, KLXE, DB, and SND. … Full story available on Benzinga.com

Voyager Therapeutics Inc.''s stock gained 16.8% in premarket trading on Tuesday after the gene therapy company said it inked a deal with Novartis [n: nvs] worth up to $1.7 billion. Novartis will pay $54 million upfront to license Voyager''s novel adeno-associated virus (AAV) capsids for use with the gene therapies it''s developing. There are several additional milestones included in the deal that would bring the total value up to $1.7 billion. Voyager''s stock is down 28.5% over the past year, while the broader S&P 500 is up 14.2%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseas

Novartis AG (NYSE: NVS ) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR ) for three capsids to use in potential gene therapies for neurological diseases, with an option to access capsids for two other targets. Data suggest that AAV capsids emerging from Voyager''s TRACER platform (Tropism Redirection of AAV by Cell type-specific Expression of RNA) … Full story available on Benzinga.com

License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional t

License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets

Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 40.88%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 5.96% and 6.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV